ADVA
16.12.2020 17:02:35 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its technology has been selected for Germany’s first open radio access network (O-RAN) proof of concept (PoC). Conducted by Telefónica Germany / O2 , the field trial is a major step towards open and disaggregated RAN architectures. Built on Ensemble Activator , ADVA’s carrier-grade network operating system (NOS) running on Edgecore’s white box switches, and the OSA 5401 , ADVA’s pluggable grandmaster clock and GNSS receiver, the PoC shows how Telefónica Germany / O2 can build disaggregated and vendor-neutral mobile networks that significantly reduce deployment and operational costs. The unique combination of ADVA’s expertise in carrier-grade NOS technology and its Oscilloquartz synchronization solution has enabled this PoC to go beyond other such trials and address the most stringent network timing requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005737/en/
“This PoC is an important stage in our journey towards open 5G networking. It shows how we can achieve the scale and agility needed for the widespread rollout of next-generation mobile services and underlines the benefits of vendor collaboration and interoperability,” commented Matthias Sauder, director, mobile access network, Telefónica Germany / O2 . “With this open RAN pilot in our O2 live network, we’re highlighting what can be achieved when industry leaders from across the value chain cooperate closely together in an open environment. We’re also proving that a disaggregated model built on affordable software-empowered hardware can deliver transport infrastructure with new levels of efficiency – for 4G as well as 5G networks in the future.”
The multi-vendor PoC is built on ADVA’s feature-rich Ensemble Activator running on Edgecore’s switching device. Developed as part of the Telecom Infra Project (TIP), the software frees mobile network operators (MNOs) from closed proprietary systems and enables them to create vendor-neutral disaggregated infrastructure with best-of-breed components. The OSA 5401’s time synchronization capabilities are also central to the Telefónica Germany / O2 trial, including its ability to send PTP sync information and corresponding messages with precise timestamping data. The OSA 5401 also makes this advanced operation compatible with 5G radio access points from third-party suppliers and augments the accurate timing needed.
“By harnessing our high-performance NOS and compact timing solution, Telefónica Germany / O2 is taking a big step towards open and disaggregated 5G networking. This PoC shows how it will be able to utilize RAN technology from multiple vendors and leverage the full benefits of separated software and hardware,” said Eli Angel, VP, product line management, ADVA. “As we’re proving in multiple real-world trials with major MNOs, our Ensemble Activator is the ideal choice for turning third-party white box switches from a wide range of suppliers into disaggregated cell site gateways (DCSGs). What’s more, our OSA 5401 provides the strict timing and interoperability needed for an open model. To put it simply, our technology is the key to making open RAN work.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005737/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom